When was Waypoint founded?

Waypoint was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Waypoint located?

Waypoint is headquartered in New York City, United States.

Who is the current CEO of Waypoint?

Xinchen Wang of Waypoint. They have also founded 1 company.

How many employees does Waypoint have?

As of Jul 31, 2026, the latest employee count at Waypoint is 20.

Is Waypoint a funded company?

Waypoint is a funded company, having raised a total of $34.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 28, 2024.

When was the latest funding round of Waypoint?

Waypoint's latest funding was a $***** Series A round on Jun 01, 2026, with participation from 6 investors.

Where does Waypoint rank among its competitors?

Waypoint ranks 144th amongst 3302 active competitors, of which 1125 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Waypoint?

Waypoint's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Waypoint - 2026 Company Profile, Team, Funding & Competitors

Waypoint is a series A company based in New York City (United States), founded in 2021 by Xinchen Wang. It operates as a Digital cell therapy platform for providers. Waypoint has raised $34.5M in funding from Amplify Partners and Hummingbird Ventures. The company has 3302 active competitors, including 1125 funded and 776 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Key Metrics

Founded Year

2021

Location

New York City, United States

Stage

Series A

Total Funding

$34.5M in 2 rounds

Latest Funding Round

Series A, Jun 01, 2026, $*****

Investors

Amplify Partners & 8 more

Ranked

144^th among 3302 active competitors

Employee Count

20 as on Jul 31, 2026

Similar Companies

Senti Bio & 138 more

View Waypoint's full profile

Waypoint has raised a total funding of $34.5M over 2 rounds. Its first funding round was on Jun 28, 2024. Its latest funding round was a Series A round on Jun 01, 2026 for $*****. 6 investors participated in its latest round. Waypoint has 9 institutional investors.

Here is the list of recent funding rounds of Waypoint:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2026	9061950	Series A	5433459	5613193	6420351	7007018
Jun 28, 2024	9209237	Seed	9123955	4101141	Hummingbird Ventures	Recode Ventures & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Waypoint's funding rounds and investors

The founders of Waypoint is Xinchen Wang. Xinchen Wang is the CEO of Waypoint.

Here are the details of Waypoint's key team members:

Xinchen Wang: Co-Founder & CEO of Waypoint.
Contact Info: 1 email address

View details of Waypoint's Founder profiles and Board Members

Waypoint's employee count trend

Waypoint has 20 employees as of Jul 26. Here is Waypoint's employee count trend over the years:

Uncover Waypoint's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Waypoint include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Waypoint, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 17 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Domain Associates, Fidelity Investments & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
144th	Waypoint 2021, New York City (United States), Series A	Digital cell therapy platform for providers	$34.5M	Amplify Partners, Hummingbird Ventures & 7 others	61/100